Notwithstanding positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. Such companies are frequently building barriers to access, such as high price restrictions and prior authorization that restrict consumer opportu… Read More